T. Rowe Price Associates
DRUG

T. Rowe Price Associates’s Bright Minds Biosciences DRUG Stock Holding History

T. Rowe Price Associates’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Buy
6,167
+1,220
+25% +$95.8K ﹤0.01% 2684
2026
Q1 		$361K Buy
4,947
+2,117
+75% +$170K ﹤0.01% 2587
2025
Q4 		$221K Buy
+2,830
New +$189K ﹤0.01% 2777

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates's DRUG Position: Q2 2026 in Review

T. Rowe Price Associates increased its Bright Minds Biosciences (DRUG) stake by 25% in Q2 2026, buying an estimated $95.8K and bringing the position to 6,167 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #2684.

T. Rowe Price Associates first reported a position in DRUG in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • T. Rowe Price Associates held 6,167 shares of Bright Minds Biosciences worth $433K as of Q2 2026.
  • T. Rowe Price Associates bought 1,220 Bright Minds Biosciences shares in Q2 2026, an estimated $95.8K.
  • Bright Minds Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2684 holding.
  • T. Rowe Price Associates first reported a position in Bright Minds Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.